scancell品牌介绍

浏览量：2361

scancell

品牌简介

ScCulle是一家临床阶段的免疫肿瘤公司，成立于1997，由诺丁汉大学Lindy Durrant教授领导的研究。该公司处于免疫肿瘤学的前沿，这是一个令人兴奋的癌症研究领域，涉及开发免疫疗法，以利用身体产生和维持有效的癌症免疫反应的能力。
癌症免疫治疗市场是生物制药行业增长最快的市场之一，预计到2022年价值1000亿美元。免疫疗法正在评估大多数癌症适应症，与化疗相比，其无与伦比的疗效和相对较低的毒性已经导致许多癌症治疗的范式转变。然而，肿瘤往往成功地避开了人体自身的自然防御机制，即免疫系统，并非所有患者都能对基于检查点抑制剂的免疫疗法做出反应。因此，治疗性疫苗有可能通过启动将无反应的肿瘤或所谓的“冷”肿瘤转化为“热”肿瘤的免疫反应来提高受益患者的比例。

Scancell is a clinical-stage immuno-oncology company which was founded in 1997 on research led by Professor Lindy Durrant at the University of Nottingham. The Company is operating at the forefront of immuno-oncology, an exciting field of cancer research which involves the development of immunotherapies to harness the body’s ability to generate and sustain an effective immune response against cancer.

The cancer immunotherapy market is one of the most rapidly growing markets within the biopharmaceutical industry, estimated to be worth USD100 billion by the year 2022. Immunotherapies are being evaluated in most cancer indications and their unrivalled efficacy and relatively low toxicity profile compared to chemotherapy is already leading to paradigm shifts in the treatment of many cancers. However, tumours often successfully evade the body’s own natural defence mechanism, the immune system, and not all patients are able to respond to checkpoint inhibitor-based immunotherapies. Therapeutic vaccines therefore have the potential to improve the proportion of patients who are able to benefit by initiating immune responses that convert unresponsive tumours, or so-called “cold” tumours, into “hot” ones.

main products